The ATMP supply chain is extremely precarious. In case of autologous therapies we are literally dealing with vein-to-vein logistics, in which the patient is the centre around which the supply chain is oriented, being both the provider of the starting material and receiver of the therapy. The highly personalized character of these therapies enforces an airtight chain of identity. Another complexity is the time critical aspect of the ATMP supply chain, where any delay or loss of the product may result in the death of a patient. Mitigating risks, ensuring undisrupted supply and tracking the product throughout the entire process, is key. This roundtable focused on the importance of data sharing throughout the ATMP value chain and the extent to which enabling technologies can exclude human error.